Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Common Equity (2018 - 2025)

Historic Common Equity for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $20.2 million.

  • China SXT Pharmaceuticals' Common Equity rose 3457.66% to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 3457.66%. This contributed to the annual value of $15.4 million for FY2025, which is 1083.47% up from last year.
  • According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Common Equity is $20.2 million, which was up 3457.66% from $15.4 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Common Equity registered a high of $20.2 million during Q3 2025, and its lowest value of $5.1 million during Q3 2023.
  • For the 5-year period, China SXT Pharmaceuticals' Common Equity averaged around $14.5 million, with its median value being $15.0 million (2022).
  • Per our database at Business Quant, China SXT Pharmaceuticals' Common Equity tumbled by 6590.69% in 2023 and then surged by 19617.74% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Common Equity (Quarter) stood at $13.8 million in 2021, then grew by 7.96% to $14.9 million in 2022, then plummeted by 65.91% to $5.1 million in 2023, then soared by 196.18% to $15.0 million in 2024, then skyrocketed by 34.58% to $20.2 million in 2025.
  • Its Common Equity was $20.2 million in Q3 2025, compared to $15.4 million in Q1 2025 and $15.0 million in Q3 2024.